Table 2.
Phosphate binders | Relative coefficient | Pill burden | Beneficial effects (pleiotropic effects or others) | Side effect | Cost |
---|---|---|---|---|---|
Aluminum hydroxide | 1.5 | Low | No | Bone accumulation | Low |
Calcium carbonate | 1.0 | High | No | Vascular and soft tissue calcification | Low |
Calcium acetate | 1.0 | High | No | Vascular and soft tissue calcification | Low |
Sevelamer carbonate/Sevelamer hydrochloride | 0.75 | High | Pleiotropic effects (lipid profiles, fibroblast growth factor 23, inflammation, uremic toxins, oxidative stress, fetuin A, and improvement of endothelial dysfunction) | Decrease absorption of vitamins A, D, E, and K; sevelamer hydrochloride (metabolic acidosis) | High |
Lanthanum carbonate (Fosrenol® chewable tablet) | 2.0 | Low | No | Bone accumulation | High |
Magnesium carbonate | 1.7 | High | No | Hypermagnesemia | Low |
Fe-citrate (Nephoxil®) | 1.14 | High | Supply oral iron | Iron overload/diarrhea? | High |